Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 8/20 | 0.34 |
| ▸ | DRD2 | P14416 | 7/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20462570 | 0.85 | OPRM1 (0.38) | OPRM1CACNA1HPREPFAP | |
| SCHEMBL19652200 | 0.82 | SIGMAR1 (0.34) | SIGMAR1CACNA1HPREPFAP | |
| SCHEMBL20462571 | 0.82 | OPRM1 (0.33) | OPRM1SIGMAR1PREPFAP | |
| SCHEMBL19658398 | 0.80 | OPRM1 (0.45) | OPRM1ROCK2P2RX7HTT | |
| SCHEMBL16501771 | 0.73 | SCN1A (0.33) | OPRM1SIGMAR1CACNA1H | |
| SCHEMBL20464427 | 0.73 | EPHX1 (0.40) | — | |
| SCHEMBL21652046 | 0.70 | — | — | |
| SCHEMBL20462573 | 0.70 | POLB (0.33) | CACNA1HPREPFAPP2RX7 | |
| SCHEMBL9965988 | 0.70 | CHRM5 (0.60) | DRD4P2RX7 | |
| SCHEMBL16421070 | 0.69 | NPSR1 (0.50) | SIGMAR1CACNA1HDRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | OPRM1 4350/4885SIGMAR1 1530/4885CACNA1H 2816/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | OPRM1 4350/4885SIGMAR1 1530/4885CACNA1H 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.